source: internationalization/trunk/TranslationSpreadsheets/WV-DIALOG-0234.txt@ 1556

Last change on this file since 1556 was 604, checked in by George Lilly, 15 years ago

Internationalization

File size: 14.5 KB
RevLine 
[604]1English French Notes Complete/Exclude
2GRADE/DIFFERENTIATION must be: 2 (Grade II)
3GRADE/DIFFERENTIATION must be: 4 (Grade IV)
4GRADE/DIFFERENTIATION =
5HISTOLOGY must be leukemia or lymphoma (9590-9948)
6No TNM classification is available for LYMPHOMA
7SUMMARY STAGE cannot be blank
8No TNM classification is available for KAPOSI'S SAROMA
9EXTENSION may not be 00 (In situ)
10ICDO-TOPOGRAPHY =
11PATHOLGIC EXTENSION =
12PATHOLOGIC EXTENSION may only be coded for PROSTATE (C61.9) cases
13REGIONAL NODES POSITIVE =
14LYMPH NODES may not be 0 (No lymph nodes)
15REGIONAL NODES EXAMINED = 99 (
16REGIONAL NODES POSITIVE must be 99 (Unk if nodes + or -, NA)
17HORMONE THERAPY =
18Only BREAST and PROSTATE cases may be coded as receiving
19endocrine surgery or endocrine radiation
20Dead
21STATUS =
22PLACE OF DEATH may not be blank
23CAUSE OF DEATH and STATE DEATH CERT may not both be blank
24White
25RACE 1 =
26RACE 2 =
27RACE 3 =
28RACE 4 =
29RACE 5 =
30For race combinations RACE 1 may not be 'White'
31A specific race code may not occur more than once
32ONC*2.11*15
33Please install ONC*2.11*15 first. Installation Halted.
34ONC*2.11*20
35ONCO*2.11*20
36Please install ONC*2.11*20 first. Installation Halted.
37The Accession Year is not 2001.
38GI stromal sarcomas (8936) are being collected via paper data form.
39The Behavior Code is not 3 (Malignant).
40Invalid Histology code.
41Select section
422001 Patient Care Evaluation Study of Gastric Cancers
43 PATIENT INFORMATION
441400.6 1. CO-MORBID CONDITIONS (YES/NO).
451571 CO-MORBID CONDITION #1.......
461571.1 CO-MORBID CONDITION #2.......
471571.2 CO-MORBID CONDITION #3.......
481571.3 CO-MORBID CONDITION #4.......
491571.4 CO-MORBID CONDITION #5.......
501571.5 CO-MORBID CONDITION #6.......
511500 2. PRIOR EXPOSURE TO RADIATION...
521501 3. ALCOHOL CONSUMPTION...........
531572 4. DURATION OF TOBACCO USE.......
54 5. MENOPAUSAL STATUS AND HORMONE
55 REPLACEMENT THERAPY..........: NA, male patient
561502 5. MENOPAUSAL STATUS AND HORMONE REPLACEMENT THERAPY..........
571503 6. H2 BLOCKER/PROTON PUMP INHIBITOR USE................
581504 7. FAMILY HISTORY OF GASTRIC CANCER.......................
591573 8. PERSONAL HISTORY OF OTHER INVASIVE MALIGNANCIES PRIOR TO THIS CANCER DIAGNOSIS....//^S X=PHDEF
60 9. ASSOCIATED BENIGN CONDTIONS:
611505 H-PYLORI INFECTION...........
621506 DUODENAL ULCER...............
631507 GASTRIC ULCER................
641509 PERNICIOUS ANEMIA............
651510 POLYPS OF STOMACH............
661511 POLYPOSIS OF SMALL OR LARGE BOWEL.......................
671513 ATROPHIC GASTRITIS...........
681514 GASTRIC METAPLASIA...........
69 10. H-PYLORI DRUGS GIVEN:
701516 PROTON PUMP INHIBITORS.......
711518 BISMUTH COMPOUNDS............
721519 11. PRIOR INTRA-ABDOMINAL SURGERY.
731520 12. YEAR OF PRIOR GASTRIC RESECTION....................
74 CO-MORBID CONDITIONS (YES/NO) equals
75 CO-MORBID CONDITION #1 may not be blank
76 CO-MORBID CONDITION #1.......: 000.00 No co-morbidities
77 CO-MORBID CONDITION #2.......:
78 CO-MORBID CONDITION #3.......:
79 CO-MORBID CONDITION #4.......:
80 CO-MORBID CONDITION #5.......:
81 CO-MORBID CONDITION #6.......:
82 ANTIBIOTICS..................: H-pylori not present
83 PROTON PUMP INHIBITORS.......: H-pylori not present
84 H2 BLOCKERS..................: H-pylori not present
85 BISMUTH COMPOUNDS............: H-pylori not present
86 TUMOR INDENTIFICATION AND DIAGNOSIS
871521 13. PERFORMANCE STATUS AT INITIAL DIAGNOSIS....................
88 14. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:
891523 FEVER/NIGHT SWEATS...........
901524 ACUTE HEMATEMESIS............
911525 TRANSFUSIONS FOR BLOOD LOSS..
921574 WEIGHT LOSS..................
931528 EARLY SATIETY................
94 15. INITIAL STAGING STUDIES:
951529 CT SCAN OF ABDOMEN...........
961530 CT SCAN OF CHEST.............
971531 CT PELVIS....................
981533 GALLIUM SCAN.................
991534 BIPEDAL LYMPHANGIOGRAM (LAG).
1001536 PET SCAN.....................
1011538 EUS (ENDOSCOPIC ULTRASOUND)..
1021539 PERITONEAL LAVAGE............
103 16. LABORATORY STUDIES:
104 17. GASTROSCOPIC EXAMINATION RESULTS:
1051545 CLINICAL/VISUAL EXAMINATION..
1061546 18. GASTRO-ESOPHAGEAL JUNCTION (SIEWART TYPE II/III)........
107 19. ANATOMIC SITE OF INITIAL HISTOLOGIC DIAGNOSIS:
1081547.3 LYMPH NODES..................
1091548 20. DATE OF FIRST TISSUE DIAGNOSIS
110 23. MOLECULAR MARKERS:
1111552 24. MITOTIC RATE..................
1121553 25. TUMOR NECROSIS................
113 26. PHENOTYPE MODALITY USED:
1141554 FLOW CYTOMETRY ON FRESH TISSUE......................
1151554.1 IMMUNOHISTOCHEMISTRY ON FROZEN TISSUE......................
1161554.2 IMMUNOHISTOCHEMISTRY ON PARAFIN EMBEDDED TISSUE.....
1171554.3 MOLECULAR GENETICS...........
1181554.4 POLYMERASE CHAIN REACTION TECHNIQUE..................
1191554.5 SOUTHERN BLOT TECHNIQUE......
1201555 27. ANN ARBOR STAGING.............
121 18. GASTRO-ESOPHAGEAL JUNCTION (SIEWART TYPE II/III)........: NA (not C16.0 or C16.1)
122 21. LAUREN'S CLASSIFICATION.......: NA (not adenocarcinoma)
123 22. GOSEKI'S CLASSIFICATION.......: NA (not adenocarcinoma)
124 24. MITOTIC RATE..................: NA (not leimyosarcoma)
125 25. TUMOR NECROSIS................: NA (not leimyosarcoma)
126 FLOW CYTOMETRY ON FRESH TISSUE......................: NA (not lymphoma)
127 IMMUNOCHEMISTRY ON FROZEN TISSUE......................: NA (not lymphoma)
128 IMMUNOHISTOCHEMISTRY ON PARAFIN EMBEDDED TISSUE.....: NA (not lymphoma)
129 MOLECULAR GENETICS...........: NA (not lymphoma)
130 POLYMERASE CHAIN REACTION TECHNIQUE...................: NA (not lymphoma)
131 SOUTHERN BLOT TECHNIQUE......: NA (not lymphoma)
132 27. ANN ARBOR STAGING.............: NA (not lymphoma)
133 FIRST COURSE OF TREATMENT - SURGERY
1341556 28. ADHERENCE OF RESECTED PRIMARY SPECIMEN.....................
1351557 29. MARGIN STATUS OF RESECTED PRIMARY SPECIMEN.............
136 30. EXTENT OF FREE MARGIN:
1371558 PROXIMAL MARGIN..............
1381558.1 DISTAL MARGIN................
139 31. RESECTION BEYOND STOMACH:
1401559.1 TRANVERSE COLON..............
1411559.5 ABDOMINAL WALL...............
1421559.6 ADRENAL GLAND................
1431559.8 SMALL INTESTINE..............
1441560 PERIGASTRIC LYMPH NODES......
1451560.1 COMMON HEPATIC LYMPH NODES...
1461560.2 CELIAC LYMPH NODES...........
1471560.3 SPLENIC LYMPH NODES..........
1481560.4 OTHER INTRA-ABDOMINAL NODES..
1491561 32. GROSSLY INVOLVED REGIONAL LYMPH NODES..................
1501562 33. HCT (HEMATOCRIT) VALUES BEFORE TRANSFUSION..................
1511563 34. TOTAL OPERATIVE BLOOD REPLACEMENT..................
1521564 35. INTRA/PERI-OPERATIVE DEATH....
153 36. COMPLICATIONS REQUIRING RE-OPERATION:
1541565 ANASTOMOTIC LEAK.............
1551565.1 STUMP LEAK...................
1561565.3 WOUND INFECTION..............
1571565.6 DEAD BOWEL...................
1581566 37. DATE OF SURGICAL DISCHARGE....
159 FIRST COURSE OF TREATMENT - RADIATION
160442 38. REGIONAL DOSE (cGy)...........
1611575 39. BOOST DOSE (cGy)..............
1621567 40. INTRA-OPERATIVE RADIATION THERAPY, DOSE (cGy)..........
1631568 41. CONCURRENT CHEMOTHERAPY.......
164 FIRST COURSE OF TREATMENT - CHEMOTHERAPY
165 42. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:
1661569 43. INTRAPERITONEAL CHEMOTHERAPY..
1671577 44. CHEMOTHERAPEUTIC TOXICITY.....
1681578 45. CHEMOTHERAPY/SURGERY SEQUENCE.
169 FIRST COURSE OF TREATMENT - IMMUNOTHERAPY
1701570 46. ADMINSTRATION OF INTERFERON...
171 No surgery of the primary site was performed.
172 Proceed to data item 38.
173 No radiation therapy was administered.
174 Code data items 38-40 to 00000.
175 Do not answer data item 41, and proceed to data item 42.
176 38. REGIONAL DOSE (cGy)...........: 00000
177 39. BOOST DOSE (cGy)..............: Not administered
178 40. INTRA-OPERATIVE RADIATION
179 THERAPY, DOSE (cGy)..........: Not administered
180 41. CONCURRENT CHEMOTHERAPY.......:
181 No chemotherapy was administered.
182 Proceed to data item 46.
183 No immunotherapy administered.
184 Proceed to Treatment Complications.
185 TREATMENT COMPLICATIONS
186 COMPLICATION #1..............: 000.00 No complications
187 CASE REGISTRATION
18881 48. INITIALS OF CASE ABSTRACTOR...
18990 49. DATE CASE WAS ABSTRACTED......
190PATIENT INFORMATION
191 1. CO-MORBID CONDITIONS:
192 CO-MORBID CONDITION #1.......: 000.00 No co-morbidities
193 CO-MORBID CONDITION #1.......:
194 CO-MORBID CONDITION #2.......:
195 CO-MORBID CONDITION #3.......:
196 CO-MORBID CONDITION #4.......:
197 CO-MORBID CONDITION #5.......:
198 CO-MORBID CONDITION #6.......:
199 2. PRIOR EXPOSURE TO RADIATION...:
200 3. ALCOHOL CONSUMPTION...........:
201 4. DURATION OF TOBACCO USE.......:
202 5. MENOPAUSAL STATUS AND HORMONE
203 REPLACEMENT THERAPY..........:
204 6. H2/BLOCKER PROTON PUMP
205 7. FAMILY HISTORY OF GASTRIC
206 8. PERSONAL HISTORY OF OTHER
207 INVASIVE MALIGNANCIES PRIOR
208 TO THIS CANCER DIAGNOSIS....:
209 9. ASSOCIATED BENIGN CONDITIONS:
210 H-PYLORI INECTION............:
211 DUODENAL ULCER...............:
212 GASTRIC ULCER................:
213 PERNICIOUS ANEMIA............:
214 POLYPS OF STOMACH............:
215 POLYPOSIS OF SMALL OR LARGE
216 ATROPHIC GASTRITIS...........:
217 GASTRIC METAPLASIA...........:
21810. H-PYLORI DRUGS GIVEN:
219 PROTON PUMP INHIBITORS.......:
220 BISMUTH COMPOUNDS............:
22111. PRIOR INTRA-ABDOMINAL SURGERY.:
22212. YEAR OF PRIOR GASTRIC
223Print Gastric Cancers PCE
224TUMOR IDENTIFICATION AND DIAGNOSIS
22513. PERFORMANCE STATUS AT INITIAL
22614. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:
227 FEVER/NIGHT SWEATS...........:
228 ACUTE HEMATEMESIS............:
229 TRANSFUSIONS FOR BLOOD LOSS..:
230 WEIGHT LOSS..................:
231 EARLY SATIETY................:
23215. INITIAL STAGING STUDIES:
233 CT SCAN OF ABDOMEN...........:
234 CT SCAN OF CHEST.............:
235 CT PELVIS....................:
236 GALLIUM SCAN.................:
237 BIPEDAL LYMPHANGIOGRAM (LAG).:
238 PET SCAN.....................:
239 EUS (ENDOSCOPIC ULTRASOUND)..:
240 PERITONEAL LAVAGE............:
24116. LABORATORY STUDIES:
24217. GASTROSCOPIC EXAMINATION RESULTS:
243 CLINICAL/VISUAL EXAMINATION..:
24418. GASTRO-ESOPHAGEAL JUNCTION
245 (SIEWART TYPE II/III)........: NA (not C16.0 or C16.1)
246 (SIEWART TYPE II/III)........:
24719. ANATOMIC SITE OF INITIAL HISTOLOGIC DIAGNOSIS:
248 LYMPH NODES..................:
24920. DATE OF FIRST TISSUE DIAGNOSIS:
25021. LAUREN'S CLASSIFICATION.......: NA (not adenocarcinoma)
25122. GOSEKI'S CLASSIFICATION.......: NA (not adenocarcinoma)
25223. MOLECULAR MARKERS:
25324. MITOTIC RATE..................: NA (not leimyosarcoma)
25425. TUMOR NECROSIS................: NA (not leimyosarcoma)
25524. MITOTIC RATE..................:
25625. TUMOR NECROSIS................:
25726. PHENOTYPE MODALITY USED:
258 FLOW CYTOMETRY ON FRESH
259 TISSUE......................: NA (not lymphoma)
260 IMMUNOCHEMISTRY ON FROZEN
261 IMMUNOHISTOCHEMISTRY ON
262 PARAFIN EMBEDDED TISSUE.....: NA (not lymphoma)
263 MOLECULAR GENETICS...........: NA (not lymphoma)
264 POLYMERASE CHAIN REACTION
265 TECHNIQUE...................: NA (not lymphoma)
266 SOUTHERN BLOT TECHNIQUE......: NA (not lymphoma)
26727. ANN ARBOR STAGING.............: NA (not lymphoma)
268 FLOW CYTOMETRY ON FRESH
269 IMMUNOCHEMISTRY ON FROZEN
270 IMMUNOHISTOCHEMISTRY ON
271 PARAFIN EMBEDDED TISSUE.....:
272 MOLECULAR GENETICS...........:
273 POLYMERASE CHAIN REACTION
274 SOUTHERN BLOT TECHNIQUE......:
27527. ANN ARBOR STAGING..............:
276FIRST COURSE OF TREATMENT - SURGERY
27728. ADHERENCE OF RESECTED PRIMARY
27829. MARGIN STATUS OF RESECTED
279 PRIMARY SPECIMAN.............:
28030. EXTENT OF FREE MARGIN:
281 PROXIMAL MARGIN..............:
282 DISTAL MARGIN................:
28331. RESECTION BEYOND STOMACH:
284 TRANVERSE COLON..............:
285 ABDOMINAL WALL...............:
286 ADRENAL GLAND................:
287 SMALL INTESTINE..............:
288 PERIGASTRIC LYMPH NODES......:
289 COMMON HEPATIC LYMPH NODES...:
290 CELIAC LYMPH NODES...........:
291 SPLENIC LYMPH NODES..........:
292 OTHER INTRA-ABDOMINAL NODES..:
29332. GROSSLY INVOLVED REGIONAL
29433. HCT (HEMATOCRIT) VALUES BEFORE
29534. TOTAL OPERATIVE BLOOD
29635. INTRA/PERI-OPERATIVE DEATH....:
29736. COMPLICATIONS REQUIRING RE-OPERATION:
298 ANASTOMOTIC LEAK.............:
299 STUMP LEAK...................:
300 WOUND INFECTION..............:
301 DEAD BOWEL...................:
30237. DATE OF SURGICAL DISCHARGE....:
303#################### #################### ####################
304#################### #################### ####################
305#################### #################### ####################
306#################### #################### ####################
307#################### #################### ####################
Note: See TracBrowser for help on using the repository browser.